Cargando…

An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems

Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release...

Descripción completa

Detalles Bibliográficos
Autores principales: Janagam, Dileep R., Wang, Lizhu, Ananthula, Suryatheja, Johnson, James R., Lowe, Tao L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039447/
https://www.ncbi.nlm.nih.gov/pubmed/27598191
http://dx.doi.org/10.3390/pharmaceutics8030028
_version_ 1782456056961564672
author Janagam, Dileep R.
Wang, Lizhu
Ananthula, Suryatheja
Johnson, James R.
Lowe, Tao L.
author_facet Janagam, Dileep R.
Wang, Lizhu
Ananthula, Suryatheja
Johnson, James R.
Lowe, Tao L.
author_sort Janagam, Dileep R.
collection PubMed
description Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release from the ISD systems during the formulation development is laborious and costly. An accelerated release method that can effectively correlate the months to years of long-term release in a short time such as days or weeks is economically needed. However, no such accelerated ISD system release method has been reported in the literature to date. The objective of the current study was to develop a short-term accelerated in vitro release method for contraceptive levonorgestrel (LNG)-containing ISD systems to screen formulations for more than 3-month contraception after a single subcutaneous injection. The LNG-containing ISD formulations were prepared by using biodegradable poly(lactide-co-glycolide) and polylactic acid polymer and solvent mixtures containing N-methyl-2-pyrrolidone and benzyl benzoate or triethyl citrate. Drug release studies were performed under real-time (long-term) conditions (PBS, pH 7.4, 37 °C) and four accelerated (short-term) conditions: (A) PBS, pH 7.4, 50 °C; (B) 25% ethanol in PBS, pH 7.4, 50 °C; (C) 25% ethanol in PBS, 2% Tween 20, pH 7.4, 50 °C; and (D) 25% ethanol in PBS, 2% Tween 20, pH 9, 50 °C. The LNG release profile, including the release mechanism under the accelerated condition D within two weeks, correlated (r(2) ≥ 0.98) well with that under real-time conditions at four months.
format Online
Article
Text
id pubmed-5039447
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50394472016-10-04 An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems Janagam, Dileep R. Wang, Lizhu Ananthula, Suryatheja Johnson, James R. Lowe, Tao L. Pharmaceutics Article Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release from the ISD systems during the formulation development is laborious and costly. An accelerated release method that can effectively correlate the months to years of long-term release in a short time such as days or weeks is economically needed. However, no such accelerated ISD system release method has been reported in the literature to date. The objective of the current study was to develop a short-term accelerated in vitro release method for contraceptive levonorgestrel (LNG)-containing ISD systems to screen formulations for more than 3-month contraception after a single subcutaneous injection. The LNG-containing ISD formulations were prepared by using biodegradable poly(lactide-co-glycolide) and polylactic acid polymer and solvent mixtures containing N-methyl-2-pyrrolidone and benzyl benzoate or triethyl citrate. Drug release studies were performed under real-time (long-term) conditions (PBS, pH 7.4, 37 °C) and four accelerated (short-term) conditions: (A) PBS, pH 7.4, 50 °C; (B) 25% ethanol in PBS, pH 7.4, 50 °C; (C) 25% ethanol in PBS, 2% Tween 20, pH 7.4, 50 °C; and (D) 25% ethanol in PBS, 2% Tween 20, pH 9, 50 °C. The LNG release profile, including the release mechanism under the accelerated condition D within two weeks, correlated (r(2) ≥ 0.98) well with that under real-time conditions at four months. MDPI 2016-09-01 /pmc/articles/PMC5039447/ /pubmed/27598191 http://dx.doi.org/10.3390/pharmaceutics8030028 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Janagam, Dileep R.
Wang, Lizhu
Ananthula, Suryatheja
Johnson, James R.
Lowe, Tao L.
An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
title An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
title_full An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
title_fullStr An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
title_full_unstemmed An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
title_short An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
title_sort accelerated release study to evaluate long-acting contraceptive levonorgestrel-containing in situ forming depot systems
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039447/
https://www.ncbi.nlm.nih.gov/pubmed/27598191
http://dx.doi.org/10.3390/pharmaceutics8030028
work_keys_str_mv AT janagamdileepr anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT wanglizhu anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT ananthulasuryatheja anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT johnsonjamesr anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT lowetaol anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT janagamdileepr acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT wanglizhu acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT ananthulasuryatheja acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT johnsonjamesr acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems
AT lowetaol acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems